Prospective evaluation of quantitative response parameter in patients with Gastrointestinal Stroma Tumor undergoing tyrosine kinase inhibitor therapy: impact on clinical outcome : cancer therapy and prevention
The purpose of this study was to determine if dual-energy CT (DECT) vital iodine tumor burden (ViTB), a direct assessment of tumor vascularity, allows reliable response assessment in patients with GIST compared to established CT criteria such as RECIST1.1 and modified Choi (mChoi). From 03/2014 to 1...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
1 December 2024
|
| In: |
International journal of cancer
Year: 2024, Jahrgang: 155, Heft: 11, Pages: 2047-2057 |
| ISSN: | 1097-0215 |
| DOI: | 10.1002/ijc.35094 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1002/ijc.35094 Verlag, kostenfrei, Volltext: http://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.35094 
|
| Verfasserangaben: | Mathias Meyer, Hideki Ota, Christina Messiou, Charlotte Benson, Thomas Henzler, Sarah A. Mattonen, Daniele Marin, Anna Bartsch, Stefan O. Schoenberg, Richard F. Riedel, Peter Hohenberger |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1908884711 | ||
| 003 | DE-627 | ||
| 005 | 20241205221326.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 241118s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/ijc.35094 |2 doi | |
| 035 | |a (DE-627)1908884711 | ||
| 035 | |a (DE-599)KXP1908884711 | ||
| 035 | |a (OCoLC)1475647754 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Meyer, Mathias |d 1986- |e VerfasserIn |0 (DE-588)1025310306 |0 (DE-627)722026021 |0 (DE-576)370193059 |4 aut | |
| 245 | 1 | 0 | |a Prospective evaluation of quantitative response parameter in patients with Gastrointestinal Stroma Tumor undergoing tyrosine kinase inhibitor therapy |b impact on clinical outcome : cancer therapy and prevention |c Mathias Meyer, Hideki Ota, Christina Messiou, Charlotte Benson, Thomas Henzler, Sarah A. Mattonen, Daniele Marin, Anna Bartsch, Stefan O. Schoenberg, Richard F. Riedel, Peter Hohenberger |
| 264 | 1 | |c 1 December 2024 | |
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Erstmals veröffentlicht: 18. Juli 2024 | ||
| 500 | |a Gesehen am 18.11.2024 | ||
| 520 | |a The purpose of this study was to determine if dual-energy CT (DECT) vital iodine tumor burden (ViTB), a direct assessment of tumor vascularity, allows reliable response assessment in patients with GIST compared to established CT criteria such as RECIST1.1 and modified Choi (mChoi). From 03/2014 to 12/2019, 138 patients (64 years [32-94 years]) with biopsy proven GIST were entered in this prospective, multi-center trial. All patients were treated with tyrosine kinase inhibitors (TKI) and underwent pre-treatment and follow-up DECT examinations for a minimum of 24 months. Response assessment was performed according to RECIST1.1, mChoi, vascular tumor burden (VTB) and DECT ViTB. A change in therapy management could be because of imaging (RECIST1.1 or mChoi) and/or clinical progression. The DECT ViTB criteria had the highest discrimination ability for progression-free survival (PFS) of all criteria in both first line and second line and thereafter treatment, and was significantly superior to RECIST1.1 and mChoi (p < .034). Both, the mChoi and DECT ViTB criteria demonstrated a significantly early median time-to-progression (both delta 2.5 months; both p < .036). Multivariable analysis revealed 6 variables associated with shorter overall survival: secondary mutation (HR = 4.62), polymetastatic disease (HR = 3.02), metastatic second line and thereafter treatment (HR = 2.33), shorter PFS determined by the DECT ViTB criteria (HR = 1.72), multiple organ metastases (HR = 1.51) and lower age (HR = 1.04). DECT ViTB is a reliable response criteria and provides additional value for assessing TKI treatment in GIST patients. A significant superior response discrimination ability for median PFS was observed, including non-responders at first follow-up and patients developing resistance while on therapy. | ||
| 650 | 4 | |a gastrointestinal stromal tumor | |
| 650 | 4 | |a imaging biomarker | |
| 650 | 4 | |a response assessment | |
| 650 | 4 | |a spectral CT | |
| 700 | 1 | |a Ota, Hideki |e VerfasserIn |4 aut | |
| 700 | 1 | |a Messiou, Christina |e VerfasserIn |4 aut | |
| 700 | 1 | |a Benson, Charlotte |e VerfasserIn |4 aut | |
| 700 | 1 | |a Henzler, Thomas |d 1980- |e VerfasserIn |0 (DE-588)134001486 |0 (DE-627)559468415 |0 (DE-576)276829948 |4 aut | |
| 700 | 1 | |a Mattonen, Sarah A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Marin, Daniele |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bartsch, Anna |e VerfasserIn |0 (DE-588)1207293148 |0 (DE-627)1693493969 |4 aut | |
| 700 | 1 | |a Schönberg, Stefan |d 1969- |e VerfasserIn |0 (DE-588)131557912 |0 (DE-627)510700624 |0 (DE-576)298584891 |4 aut | |
| 700 | 1 | |a Riedel, Richard F. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hohenberger, Peter |d 1953- |e VerfasserIn |0 (DE-588)1025311469 |0 (DE-627)72202875X |0 (DE-576)370195574 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of cancer |d Bognor Regis : Wiley-Liss, 1966 |g 155(2024), 11 vom: Dez., Seite 2047-2057 |h Online-Ressource |w (DE-627)269532781 |w (DE-600)1474822-8 |w (DE-576)079876129 |x 1097-0215 |7 nnas |a Prospective evaluation of quantitative response parameter in patients with Gastrointestinal Stroma Tumor undergoing tyrosine kinase inhibitor therapy impact on clinical outcome : cancer therapy and prevention |
| 773 | 1 | 8 | |g volume:155 |g year:2024 |g number:11 |g month:12 |g pages:2047-2057 |g extent:11 |a Prospective evaluation of quantitative response parameter in patients with Gastrointestinal Stroma Tumor undergoing tyrosine kinase inhibitor therapy impact on clinical outcome : cancer therapy and prevention |
| 856 | 4 | 0 | |u https://doi.org/10.1002/ijc.35094 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u http://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.35094 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20241118 | ||
| 993 | |a Article | ||
| 994 | |a 2024 | ||
| 998 | |g 1025311469 |a Hohenberger, Peter |m 1025311469:Hohenberger, Peter |d 60000 |e 60000PH1025311469 |k 0/60000/ |p 11 |y j | ||
| 998 | |g 131557912 |a Schönberg, Stefan |m 131557912:Schönberg, Stefan |d 60000 |d 62900 |e 60000PS131557912 |e 62900PS131557912 |k 0/60000/ |k 1/60000/62900/ |p 9 | ||
| 998 | |g 134001486 |a Henzler, Thomas |m 134001486:Henzler, Thomas |d 60000 |e 60000PH134001486 |k 0/60000/ |p 5 | ||
| 998 | |g 1025310306 |a Meyer, Mathias |m 1025310306:Meyer, Mathias |p 1 |x j | ||
| 999 | |a KXP-PPN1908884711 |e 4616118825 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"origin":[{"dateIssuedDisp":"1 December 2024","dateIssuedKey":"2024"}],"relHost":[{"type":{"media":"Online-Ressource","bibl":"periodical"},"note":["Gesehen am 28.02.08","Darin: Predictive oncology"],"titleTranslated":[{"translated":"Journal international du cancer"}],"title":[{"title_sort":"International journal of cancer","title":"International journal of cancer","subtitle":"publication of the International Union against Cancer (UICC) = Journal international du cancer"}],"recId":"269532781","titleAlt":[{"title":"Predictive oncology"}],"language":["eng"],"id":{"doi":["10.1002/(ISSN)1097-0215"],"zdb":["1474822-8"],"issn":["1097-0215"],"eki":["269532781"]},"physDesc":[{"extent":"Online-Ressource"}],"part":{"volume":"155","pages":"2047-2057","year":"2024","extent":"11","issue":"11","text":"155(2024), 11 vom: Dez., Seite 2047-2057"},"corporate":[{"roleDisplay":"Herausgebendes Organ","display":"International Union against Cancer","role":"isb"}],"origin":[{"dateIssuedKey":"1966","publisherPlace":"Bognor Regis","dateIssuedDisp":"1966-","publisher":"Wiley-Liss"}],"disp":"Prospective evaluation of quantitative response parameter in patients with Gastrointestinal Stroma Tumor undergoing tyrosine kinase inhibitor therapy impact on clinical outcome : cancer therapy and preventionInternational journal of cancer","pubHistory":["1.1966 -"]}],"name":{"displayForm":["Mathias Meyer, Hideki Ota, Christina Messiou, Charlotte Benson, Thomas Henzler, Sarah A. Mattonen, Daniele Marin, Anna Bartsch, Stefan O. Schoenberg, Richard F. Riedel, Peter Hohenberger"]},"recId":"1908884711","physDesc":[{"extent":"11 S."}],"id":{"eki":["1908884711"],"doi":["10.1002/ijc.35094"]},"language":["eng"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"person":[{"display":"Meyer, Mathias","family":"Meyer","roleDisplay":"VerfasserIn","role":"aut","given":"Mathias"},{"roleDisplay":"VerfasserIn","display":"Ota, Hideki","family":"Ota","given":"Hideki","role":"aut"},{"role":"aut","given":"Christina","display":"Messiou, Christina","family":"Messiou","roleDisplay":"VerfasserIn"},{"given":"Charlotte","role":"aut","display":"Benson, Charlotte","family":"Benson","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","display":"Henzler, Thomas","family":"Henzler","role":"aut","given":"Thomas"},{"role":"aut","given":"Sarah A.","roleDisplay":"VerfasserIn","display":"Mattonen, Sarah A.","family":"Mattonen"},{"family":"Marin","display":"Marin, Daniele","roleDisplay":"VerfasserIn","role":"aut","given":"Daniele"},{"display":"Bartsch, Anna","family":"Bartsch","roleDisplay":"VerfasserIn","role":"aut","given":"Anna"},{"family":"Schönberg","display":"Schönberg, Stefan","roleDisplay":"VerfasserIn","role":"aut","given":"Stefan"},{"role":"aut","given":"Richard F.","display":"Riedel, Richard F.","family":"Riedel","roleDisplay":"VerfasserIn"},{"display":"Hohenberger, Peter","family":"Hohenberger","roleDisplay":"VerfasserIn","given":"Peter","role":"aut"}],"title":[{"subtitle":"impact on clinical outcome : cancer therapy and prevention","title":"Prospective evaluation of quantitative response parameter in patients with Gastrointestinal Stroma Tumor undergoing tyrosine kinase inhibitor therapy","title_sort":"Prospective evaluation of quantitative response parameter in patients with Gastrointestinal Stroma Tumor undergoing tyrosine kinase inhibitor therapy"}],"note":["Erstmals veröffentlicht: 18. Juli 2024","Gesehen am 18.11.2024"]} | ||
| SRT | |a MEYERMATHIPROSPECTIV1202 | ||